# Surgical Oncology (breast) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Rachel Carson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML041-SYN
- Date: 2026-03-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Henrietta Solís-Abernathy, MD
- Calendar frame: modern shifted

- Requested by: Margaret Vance-Okonkwo, MD

## Reason for consultation

New palpable left breast mass, clinically suspicious for cancer, in a postmenopausal woman of 52. Diagnostic mammography and ultrasound are booked this week, with core biopsy if indicated. Please see her once the results are available to discuss surgical options and axillary staging with her. **S**

## History

Ms. Carson is seen at the request of Dr. Vance-Okonkwo with a left breast mass she found about three weeks ago. Diagnostic mammography and ultrasound a week ago showed a 2.4 cm irregular spiculated mass at 2 o'clock, BI-RADS 5, in breasts of scattered fibroglandular density, with normal axillary nodes on ultrasound. The core biopsy five days ago shows invasive ductal carcinoma, grade 2, ER 95 percent, PR 80 percent, HER2 1+ (negative), Ki-67 22 percent. She has no bone pain, cough, headaches, or weight loss. She had a benign left breast tumor removed about ten years ago. She asked at the start what the biopsy showed and was told directly that it is breast cancer; she asked to hear the options with their trade-offs before deciding. **S**

## Examination

| System | Finding |
|---|---|
| General | Composed and attentive; takes notes |
| Breasts | Left breast: 2.5 cm hard, irregular mass at 2 o'clock, 7 cm from the nipple, mobile on the chest wall; biopsy site bruised; no skin dimpling or nipple change. Right breast normal. Breasts moderate in size |
| Lymph nodes | No axillary, supraclavicular, or infraclavicular nodes |

BP 130/80 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 59 kg; BMI 22.2 kg/m². All vital signs are synthetic.

## Data reviewed

Diagnostic mammogram and ultrasound images and reports; core biopsy pathology with ER, PR, HER2, and Ki-67; Dr. Vance-Okonkwo's referral and examination. PHQ-9: 6; GAD-7: 8. All results are synthetic.

## Assessment

1. **Invasive ductal carcinoma of the left breast, clinical T2 N0 M0, hormone receptor positive, HER2 negative** (C50.412). Early breast cancer suitable for surgery first. The tumor is single and can be removed with clear margins and a good appearance, so breast-conserving surgery followed by radiation gives the same survival as mastectomy. Both were explained to her with their trade-offs: radiation for several weeks with breast conservation, or no radiation in most cases but loss of the breast, with or without reconstruction, with mastectomy. She chose breast-conserving surgery. MRI is not needed for a single lesion in breasts that are not dense, and staging scans are not indicated at this stage without symptoms. **S**
2. **Axillary staging**. The axilla is normal on examination and ultrasound, so sentinel lymph node biopsy is the standard. If one or two sentinel nodes are involved, axillary dissection adds arm swelling without improving survival when whole-breast radiation follows; she would then have radiation that may include the regional nodes. **S**
3. **Genetic risk**. Germline testing is recommended for everyone with breast cancer diagnosed at 65 or younger. A pathogenic variant could change the operation, so the result should be known before surgery. **S**
4. **What to expect after surgery**. Endocrine therapy will be recommended because the cancer is strongly hormone receptor positive. Radiation follows breast conservation. Whether chemotherapy or a CDK4/6 inhibitor adds benefit depends on the nodal result and a recurrence score on the specimen; she will hear those numbers before any decision. **S**

## Recommendations

1. Left lumpectomy with localization of the biopsy clip and sentinel lymph node biopsy within three weeks; no breast MRI and no staging scans.
2. If one or two sentinel nodes are involved, no axillary dissection, with whole-breast radiation and regional nodal radiation considered by radiation oncology.
3. Germline multigene panel testing with genetic counseling now, with the result before surgery.
4. Baseline arm measurements before surgery for later lymphedema checks; acetaminophen rather than nonsteroidal anti-inflammatory drugs after surgery because of her recent ulcer.
5. A recurrence score on the surgical specimen and review at the multidisciplinary breast clinic with medical and radiation oncology, who will give her the expected benefit and side effects of each option in numbers.
6. Every result to be given to her directly, in plain words and with a written copy, before it is shared with anyone else, and only with the people she names.

## Strengths and supports

- Supports: a close friend and her editor; she shares health news with very few people **S**

## Communication

Discussed with Dr. Vance-Okonkwo the same day; Ms. Carson has a written summary of her choice and the next steps and agreed to the plan. **S**

## Follow-up

Breast surgical oncology will see her at the pre-operative visit with the genetic result, and one week after surgery with the pathology. Primary care continues distress screening and coordinates the oncology reviews. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Code of Medical Ethics Opinion 2.1.3: Withholding Information from Patients (2016), American Medical Association
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017;35(31):3618-3632 (2017), American Society of Clinical Oncology
- Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 2021;39(27):3056-3082 (2021), American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)
